A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
ApexOnco Front Page
Recent articles
The company is to test its KLK2-targeting pasritamig in a late-line setting.
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.
Golcadomide will begin a new pivotal trial in follicular lymphoma.
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
The group expects to raise nearly $170m.
Can the company add a Car-T string to its stem cell transplant bow?
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
